Biomea Fusion, Inc. (BMEA) NASDAQ
2.21
+0.28(+14.51%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.21
+0.28(+14.51%)
Currency In USD
| Previous Close | 2.21 |
| Open | 1.98 |
| Day High | 2.21 |
| Day Low | 1.95 |
| 52-Week High | 3.08 |
| 52-Week Low | 0.87 |
| Volume | 6,813 |
| Average Volume | 1.35M |
| Market Cap | 131.49M |
| PE | -1.87 |
| EPS | -1.18 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 1.54 |
| Change | 2.21 |
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapiesSuccessfully
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will p
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
GlobeNewswire Inc.
Dec 09, 2025 11:35 PM GMT
Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, In